Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;18(7-8):370-3.
doi: 10.1007/BF03091794.

Dronedarone in patients with atrial fibrillation

Affiliations

Dronedarone in patients with atrial fibrillation

N M S de Groot et al. Neth Heart J. 2010 Aug.

Abstract

Dronedarone is a recently developed new class III antiarrhythmic drug which possesses electrophysiological properties of all four Vaughan-Williams classes. An important difference with amiodarone is that it does not contain an iodine component and therefore lacks the iodine-related adverse effects. Based on currently available data, dronedarone can not be recommended as first-line therapy for either rhythm or rate control. We recommend to initiate rhythm or rate control with drugs as indicated in the 2006 guidelines of the ESC and other organisations. As amiodarone, dronedarone can be given to patients for whom standard drug therapy is not effective, or limited by (severe) side effects, although it is less effective than amiodarone. Nevertheless, it may be considered to give dronedarone initially to patients who would otherwise have received amiodarone, since the latter has more severe side effects than the former drug. The daily dosage of dronedarone is oral administration, 400 mg twice daily. Dronedarone is contraindicated in patients with impaired left ventricular function (NYHA class III/IV) and haemodynamic instability. (Neth Heart J 2010;18:370-3.).

Keywords: Donedarone; Amiodarone; Anti-Arrhytmia Agents; Atrial Fibrillation.

PubMed Disclaimer

Similar articles

Cited by

  • [How to: clinical use of antiarrhythmic drugs].
    Hillmann HAK, Betz K, Linz D, Duncker D. Hillmann HAK, et al. Herzschrittmacherther Elektrophysiol. 2023 Mar;34(1):82-90. doi: 10.1007/s00399-022-00919-y. Epub 2023 Jan 24. Herzschrittmacherther Elektrophysiol. 2023. PMID: 36692540 Review. German.

References

    1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006;27:1979-2030. - PubMed
    1. Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol. 2008;6:228-36. - PubMed
    1. Chan AL, Hsieh HJ, Hsieh YA, Lin SJ. Fatal amiodarone-induced hepatotoxicity: a case report and literature review. Int J Clin Pharmacol Ther. 2008;46:96-101. - PubMed
    1. Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol. 2008;66:82-7. - PMC - PubMed
    1. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;31:127-41. - PubMed

LinkOut - more resources